Alyeska Investment Group
ATRS

Alyeska Investment Group’s Antares Pharma, Inc. ATRS Stock Holding History

Alyeska Investment Group’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-920,931
Closed -$2.15M – 578
2016
Q4 		$2.15M Sell
920,931
-118,859
-11% -$226K 0.02% 386
2016
Q3 		$1.75M Buy
1,039,790
+172,980
+20% +$212K 0.02% 395
2016
Q2 		$910K Buy
866,810
+17,586
+2% +$17K 0.01% 389
2016
Q1 		$739K Buy
849,224
+26,255
+3% +$25.4K 0.01% 361
2015
Q4 		$996K Buy
822,969
+33,553
+4% +$46.7K 0.01% 340
2015
Q3 		$1.34M Buy
789,416
+173,126
+28% +$339K 0.02% 366
2015
Q2 		$1.28M Buy
+616,290
New +$1.49M 0.01% 390

Other funds holding ATRS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Alyeska Investment Group's ATRS Position: Q1 2017 in Review

Alyeska Investment Group sold out of Antares Pharma, Inc. (ATRS) in Q1 2017, closing a stake of 920,931 shares — an estimated $2.15M sold.

Alyeska Investment Group first reported a position in ATRS in Q2 2015 and held it in 7 quarters. The position peaked at $2.15M in Q4 2016. 85 funds tracked by Wall St. Rank hold ATRS as of Q1 2017.

  • Alyeska Investment Group reported no remaining Antares Pharma, Inc. position as of Q1 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 920,931 Antares Pharma, Inc. shares in Q1 2017, an estimated $2.15M.
  • Alyeska Investment Group first reported a position in Antares Pharma, Inc. in Q2 2015 and held it in 7 quarters.
  • Alyeska Investment Group's Antares Pharma, Inc. position peaked at $2.15M in Q4 2016.
  • 85 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q1 2017.

Based on Alyeska Investment Group's 13F filing for Q1 2017, filed 15 May 2017.